Roche Diagnostics to get indirect boon from new test
New drug for metastatic melanoma packaged with genetic test should help Roche sell more of its cobas 4800 laboratory testing systems.
Life Science & Biotech
Articles
Glick support boosts IU eye research
A $10 million research endowment at the Eugene and Marilyn Glick Eye Institute has attracted seven new researchers to the Indiana University School of Medicine’s Ophthalmology Department.
Inventor on quest to bring medical device to market
Licensed practical nurse Nic Davis invented a device to kill and prevent the introduction of microorganisms that collect at catheter ports.
Health care VC slows in 2011
Four Hoosier companies attracted more than $10.5 million, down from 10 companies that attracted $18.5 million during the first half of 2010.
Zimmer playing hardball with plaintiffs’ lawyers
The Warsaw-based company has sued seven law firms this year and sent warning letters to at least three more, saying their ads and Internet postings distorted the safety record of its $1.8 billion-a-year knee business.
Medical implant maker plans move from northern Indiana
Rochester Medical Implants plans to move operations from Rochester to Noblesville in October. The company has 28 employees.
Packaging manufacturer plans to expand, add 80 jobs
Indianapolis-based DGP Intelsius LLC, a manufacturer and distributor of temperature-controlled packaging, announced on Tuesday morning that it plans to add 80 jobs by 2014 as part of an $870,000 expansion.
Eli Lilly’s Elanco unit blossoming at just the right time
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
Indiana life sciences leaders look toward the future
Former Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry in Indiana to venture capital and Purdue’s Discovery Park.
More life sciences firms opt to launch products in Europe
The U.S. Food and Drug Administration’s growing reputation for unpredictability is spurring some Indianapolis companies to join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations occurring in their backyards.
Angel investment firm adds 3rd chapter for life sciences
StepStone Business Partners has added a chapter in biotech hotbed Warsaw as part of what it hopes will eventually become a statewide network.
Dow AgroSciences reports record sales, higher earnings
Second-quarter revenue for the Indianapolis-based company increased 18 percent, to $1.5 billion. The company attributed the gain to higher prices and stronger demand for its products.
Pfizer won’t break up animal unit for potential Lilly bid
Pfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
Tech district could boost Indianapolis’ convention business
The Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
Lilly loses bid to end revived Zyprexa U.K. patent case
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
Timing good for 2-in-1 biotech drugs
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
Lilly plans more investment in two-in-one drugs
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
Lilly CEO: Immigration, tax laws slow innovation
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
City leaders look to 16th Street as future tech hub
Officials on Thursday shared details of a long-term plan to redevelop an industrial stretch northwest of downtown with the goal of attracting hundreds of residents and dozens of high-tech companies to the area.
2010 was great for Indiana’s 100 largest companies
Despite enjoying rising revenues and profits, companies haven’t followed with big increases in job numbers.